EGFR and head and neck squamous cell carcinoma: to determine the efficacy and safety profile of lapatinib in patients with recurrent or metastatic HNSCC, the results suggested that lapatinib as a single agent was well-tolerated but was a weak EGFR inhibitor and lacked efficacy (57).